Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis. - Fuhr, Rainard; Cook, David; Ridden, John; Nield, Kerry; Leigh, Emma; Cook, Julie; Davies‐Strickleton, Heather; Dobmeyer, Juergen (Mycoses, 2022)